Masimo (MASI) Proxy Filing summary

Executive summary

• A definitive merger agreement was signed for an all-cash acquisition at $180.00 per share, valuing the transaction at $9.9 billion, with unanimous board approval from both parties.

• The merger will result in the target company becoming a wholly owned subsidiary, operating as a standalone business unit within the acquirer's diagnostics segment.

• The transaction is expected to close in the second half of 2026, subject to regulatory and shareholder approvals.

• A press release and proxy materials will be distributed to shareholders, and the company will not host an earnings call due to the pending transaction.

Voting matters and shareholder proposals

• Shareholders will vote on the adoption of the merger agreement and related matters at a special meeting, with a majority required for approval.

• A voting and support agreement was executed with a major shareholder, committing their shares in favor of the merger and against competing proposals.

• The agreement includes provisions for potential superior proposals, allowing the board to change its recommendation under certain conditions.

Board of directors and corporate governance

• Both boards unanimously approved the transaction, determining it to be in the best interests of their respective shareholders.

• The surviving corporation’s board will be composed of the directors of the merger subsidiary immediately prior to closing.

• The company’s officers will remain in place post-merger until successors are appointed.